Effects of weight reduction on serum vaspin concentrations in obese subjects: Modification by insulin resistance

Obesity

Volumn 18, Issue 11, 2010, Pages 2105-2110

  Chang, Hye M ^a   Lee, Hea J ^a   Park, Hye S ^a   Kang, Jae H ^b   Kim, Kyung S ^c   Song, Young S ^a   Jang, Yeon J ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; LACTONE; SERINE PROTEINASE INHIBITOR; SERPINA12 PROTEIN, HUMAN; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; BLOOD; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; FEMALE; HIP; HISTOLOGY; HUMAN; INSULIN RESISTANCE; LIFESTYLE; LONGITUDINAL STUDY; MALE; OBESITY; PHYSIOLOGY; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; BODY MASS INDEX; BODY WEIGHT; FEMALE; HIP; HUMANS; INSULIN RESISTANCE; LACTONES; LIFE STYLE; LONGITUDINAL STUDIES; MALE; OBESITY; SERPINS; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 78049258257     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2010.60     Document Type: Article

References (27)

1. Frayn KN. Visceral fat and insulin resistance-causative or correlative? Br J Nutr 2000;83(Suppl 1):S71-S77.
2. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93:S57-S63.
3. Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003;27 (Suppl 3):S25-S28.
4. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009;54:1847-1856.
5. Ahima RS, Osei SY. Adipokines in obesity. Front Horm Res 2008;36: 182-197.
6. Inadera H. The usefulness of circulating adipokine levels for the assessment of obesity-related health problems. Int J Med Sci 2008;5: 248-262.
7. Hida K, Wada J, Zhang H et al. Identification of genes specifically expressed in the accumulated visceral adipose tissue of OLETF rats. J Lipid Res 2000;41:1615-1622.
8. Li Q, Chen R, Moriya J et al. A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J Int Med Res 2008;36:625-629.
9. Hida K, Wada J, Eguchi J et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610-10615.
10. Klöting N, Berndt J, Kralisch S et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006;339:430-436.
11. Youn BS, Klöting N, Kratzsch J et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008;57:372-377.
12. Tan BK, Heutling D, Chen J et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008;57:1501-1507.
13. Matthews DR, Hosker J P, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
14. Chang HM, Park HS, Park CY, Song YS, Jang YJ. Association between serum vaspin concentrations and visceral adipose tissue in Korean subjects. Metabolism 2010; e-pub ahead of print 6 January 2010.
15. Suleymanoglu S, Tascilar E, Pirgon O et al. Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract 2009;84:325-328.
16. Pouliot MC, Després J P, Lemieux S et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-468.
17. Smith SR, Zachwieja JJ. Visceral adipose tissue: a critical review of intervention strategies. Int J Obes Relat Metab Disord 1999;23:329-335.
18. Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obes (Lond) 2008;32:619-628.
19. Kempf K, Rose B, Illig T et al. Vaspin (SERPINA12) Genotypes and Risk of Type 2 Diabetes: Results from the MONICA/KORA studies. Exp Clin Endocrinol Diabetes 2010;118:184-189.
20. Zvonic S, Lefevre M, Kilroy G et al. Secretome of primary cultures of human adipose-derived stem cells: modulation of serpins by adipogenesis. Mol Cell Proteomics 2007;6:18-28.
21. Seeger J, Ziegelmeier M, Bachmann A et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008;93:247-251.
22. Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
23. Vogeser M, König D, Frey I et al. Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clin Biochem 2007;40:964-968.
24. Clasey JL, Bouchard C, Teates CD et al. The use of anthropometric and dual-energy X-ray absorptiometry (DXA) measures to estimate total abdominal and abdominal visceral fat in men and women. Obes Res 1999;7:256-264.
25. Lee K, Lee S, Kim YJ. Waist circumference, dual-energy X-ray absortiometrically measured abdominal adiposity, and computed tomographically derived intra-abdominal fat area on detecting metabolic risk factors in obese women. Nutrition 2008;24:625-631.
26. Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs 1999;58:743-760. (Pubitemid 29520518)
27. Bougoulia M, Triantos A, Koliakos G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens) 2006;5:259-269.